Prominent publications by Gary M Clark

KOL Index score: 18739

BACKGROUND: AIB1 (SRC-3) is an estrogen receptor (ER) coactivator that, when overexpressed in cultured cells, can reduce the antagonist activity of tamoxifen-bound ERs. Signaling through the HER-2 receptor pathway activates AIB1 by phosphorylation. To determine whether high AIB1 expression alone or together with HER-2 reduces the effectiveness of tamoxifen in breast cancer patients, we quantified expression of AIB1 and HER-2 in tumors from breast cancer patients with long-term clinical ...

Also Ranks for: Breast Cancer |  tamoxifen resistance |  aib1 expression |  receptor coactivator |  tumor blotting
KOL Index score: 16531

Results of estrogen receptor (ER) and progesterone receptor (PgR) ligand-binding assays (LBAs) are strongly correlated with ER and PgR by immuno-histochemistry (IHC). To investigate whether ER and PgR by IHC are also strongly correlated with tamoxifen response, time to treatment failure (TTF) and overall survival (OS), the results of the 2 methods were directly compared in 205 patients with ER(+) metastatic breast cancer treated with daily tamoxifen (Southwest Oncology Group protocol ...

Also Ranks for: Metastatic Breast Cancer |  estrogen receptor |  pgr ihc |  tamoxifen response |  menopausal status
KOL Index score: 15611

Using permanent-section immunohistochemistry, we investigated the role of HER-2/neu in the development and progression of human breast cancer by measuring its overexpression in a series of hyperplastic (n = 30), dysplastic (n = 15), and malignant neoplastic (n = 708) lesions of ductal epithelium and by evaluating the relationships between overexpression and clinicopathologic features known to have prognostic significance in these lesions. The neoplasms included pure ductal carcinoma in ...

Also Ranks for: Her2 Neu |  idc dcis |  situ carcinoma |  invasive breast |  intraductal female humans
KOL Index score: 15559

BACKGROUND: Usual ductal hyperplasia (UDH), atypical ductal hyperplasia (ADH), and ductal carcinoma in situ (DCIS) are risk factors for invasive breast cancer (IBC), suggesting that these lesions may be direct precursors of IBC. To identify genetic changes that may be important in the early development of precursor lesions and their progression to malignant or invasive disease, we examined 399 putative precursors (211 UDH, 51 ADH, 81 non-comedo DCIS, and 56 comedo DCIS) for loss of ...

Also Ranks for: Breast Lesions |  dcis ibc |  putative precursors |  genetic loci |  hyperplasia adh
KOL Index score: 14677

PURPOSE: This report describes the quality of life (QOL) findings of a randomized placebo controlled study of erlotinib, an epidermal growth factor receptor inhibitor, in patients with non-small-cell lung cancer (NSCLC).

PATIENTS AND METHODS: This double-blind phase III trial randomly assigned 731 patients with NSCLC who had progressed after prior chemotherapy to erlotinib 150 mg daily or placebo, with survival as the primary study outcome. QOL was assessed by European Organisation for ...

Also Ranks for: Life Qol |  erlotinib patients |  lung cancer |  cough dyspnea |  symptom improvement
KOL Index score: 14304

PURPOSE: Patients with advanced pancreatic cancer have a poor prognosis and there have been no improvements in survival since the introduction of gemcitabine in 1996. Pancreatic tumors often overexpress human epidermal growth factor receptor type 1 (HER1/EGFR) and this is associated with a worse prognosis. We studied the effects of adding the HER1/EGFR-targeted agent erlotinib to gemcitabine in patients with unresectable, locally advanced, or metastatic pancreatic cancer.


Also Ranks for: Advanced Pancreatic Cancer |  patients erlotinib |  canada clinical trials |  phase iii trial |  aged pancreatic
KOL Index score: 13922

Urokinase plasminogen activator (uPA) is a proteolytic enzyme involved in degradation of the extracellular matrix during cancer invasion. The levels of uPA and its inhibitor PAI-1 in tumor extracts have previously been demonstrated to be of prognostic value in breast cancer as well as other types of cancer. We have previously characterized a specific cell surface receptor for uPA (uPAR) which strongly enhances the catalytic activity of uPA and is expressed during mammary cancer invasion. ...

Also Ranks for: Breast Cancer |  upa upar |  immunosorbent assay |  urokinase receptor |  tissue extracts
KOL Index score: 13690

PURPOSE: Immunohistochemistry (IHC) is a newer technique for assessing the estrogen receptor (ER) status of breast cancers, with the potential to overcome many of the shortcomings associated with the traditional ligand-binding assay (LBA). The purpose of this study was to evaluate the ability of ER status determination by IHC, compared with LBA, to predict clinical outcome-especially response to adjuvant endocrine therapy-in a large number of patients with long-term clinical ...

Also Ranks for: Adjuvant Endocrine Therapy |  estrogen receptor status |  diagnostic receptors |  ihc lba |  predicting response
KOL Index score: 13689

PURPOSE: To determine whether progesterone receptor (PgR) status provides additional value to estrogen receptor (ER) status and improves prediction of benefit from endocrine treatment among patients with primary breast cancer.

PATIENTS AND METHODS: Clinical outcomes of patients in two large databases were analyzed as a function of steroid receptor status. The first database (PP), contained 3,739 patients who did not receive any systemic adjuvant therapy and 1,688 patients who received ...

Also Ranks for: Adjuvant Endocrine Therapy |  receptor status |  endocrine treatment |  local neoplasms |  positive patients
KOL Index score: 13010

INTRODUCTION: Invasive lobular carcinoma (ILC) comprises approximately 10% of breast cancers and appears to have a distinct biology. Because it is less common than infiltrating ductal carcinoma (IDC), few data have been reported that address the biologic features of ILC in the context of their clinical outcome. In the present study we undertook an extensive comparison of ILC and IDC using a large database to provide a more complete and reliable assessment of their biologic phenotypes and ...

Also Ranks for: Idc Ilc |  lobular carcinoma |  estrogen receptors |  tumor characteristics |  breast neoplasms

Key People For Breast Cancer

Top KOLs in the world
Ahmedin * *****
united states breast cancer addis ababa
Gabriel * **********
breast cancer neoadjuvant chemotherapy estrogen receptors
Rebecca * ******
united states colorectal cancer incidence rates
Charles * *****
breast cancer gene expression intrinsic subtypes
Freddie *** ****
cancer incidence nordic countries mortality rates
Jacques ******
cancer incidence global burden latin america

Gary M Clark:Expert Impact

Concepts for whichGary M Clarkhas direct influence:Breast cancer,  Estrogen receptors,  Progesterone receptor,  Estrogen receptor,  Human tumor cloning,  Human breast cancer,  Progesterone receptors,  Temporomandibular disorders.

Gary M Clark:KOL impact

Concepts related to the work of other authors for whichfor which Gary M Clark has influence:Breast cancer,  Estrogen receptor,  Cell lung,  Situ hybridization,  Growth factor,  Gene expression,  Monoclonal antibodies.



Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

Array BioPharma, Inc., Boulder, CO USA | Affiliations of authors: ST-Consulting, Glen Echo, MD (SET); Biostatistics and Data Management, ArrayBiopharma, Inc, Boulder, CO (GMC); Ontario Institute for Cancer Research, Toronto, ON, Canada (JED); Biometr